Psychedelic-Assisted Therapy

We require anyone interested in receiving TheraPsil's support to carefully read over all of our Frequently Asked Questions.

By reviewing these FAQs you will become informed about Psychedelic-Assisted Psychotherapy, TheraPsil, Project Solace and how we may be able to help you.

When considering if psychedelic therapy is right for you, it’s important to be aware of the costs involved. Unfortunately, psilocybin and MDMA-assisted therapy are not yet medically regulated in Canada, and are not covered by public healthcare. Financial investment is required at multiple stages of the process.

The overall cost of therapy—including intake coordination, prescriber oversight, therapeutic preparation and integration, and medicine administration—can range from $2,500 to $6,500, depending on your care team, treatment plan, and whether you are accessing psilocybin through the Special Access Program (SAP). Your healthcare providers will discuss specific fees with you directly, including whether sliding-scale rates or private insurance may apply.

TheraPsil charges a one-time, non-refundable fee of $1,000 to access our intake system. This supports our nonprofit work advocating for legal, safe psychedelic therapy in Canada.

For a deeper understanding of what these costs include, please visit our Understanding Costs page.

A contraindication is a reason a person should not receive a particular treatment due to the risk of significant medical or psychological harm.

Please note that TheraPsil is not a medical organization, therefore we are unable to provide any kind of medical consultation or advice pertaining to your treatment.

Psychedelics are contraindicated if someone is pregnant, or has a history of epilepsy/other seizure disorder, or severe cardiovascular disease including uncontrolled blood pressure, heart failure, coronary artery disease or previous heart attack or stroke.

Because psychedelics work by activating Serotonin receptors in the brain, they can lead to a life threatening condition called Serotonin Syndrome if used in conjunction with other medications or substances that also increase Serotonin levels in the brain. As a result, they are contraindicated in people using medications like SSRI or MAO-I antidepressants who are not able to be weaned off of these medications before treatment.

Those with a personal or family history of primary psychotic or affective disorders like Schizophrenia, Schizoaffective disorder, or Bipolar 1 disorder. It can also be dangerous for people who experience psychotic symptoms in the setting of depression.

Reference

Health Canada currently approves patients who have been diagnosed with End-of-life distress/Terminal Illness, Treatment-Resistant Depression (TRD) or Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) that have not responded to standard treatments.

We believe that all Canadians in medical need should have access to safe and effective psychedelic-assisted psychotherapy. Patients currently accessing psychedelics in Canada are those who meet the eligibility criteria of Health Canada’s Special Access Program. If you do not see yourself reflected in SAP’s criteria list above, but would still like to explore an application for legal access, email our team.